Several possible studies
Story checked
UCLA researcher wins the 2026 Albany Prize for revolutionary cancer therapy discoveries (opens in a new tab)
news-medical.net · 2026-10-06
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
UCLA researcher wins the 2026 Albany Prize for revolutionary cancer therapy discoveries
news-medical.net · 2026-10-06
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Cited as backgroundpresented as earlier work
https://www.uclahealth.org/news/release/dr-dennis-slamon-awarded-2026-albany-prize-developing
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedDennis Slamon was awarded the 2026 Albany Prize for discoveries that transformed the understanding and treatment of cancer.View evidenceHide evidence
As stated2026 Albany Prize
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 8Not checkedSlamon shares the prize with Tony Hunter, and the two are being recognized for breakthrough discoveries in cancer biology that helped reveal the molecular mechanisms driving cancer and led to lifesaving treatments for millions of people worldwide.View evidenceHide evidence
As statedmillions of people worldwide
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 8Not checkedSlamon is best known for research that led to identification of HER2-positive breast cancer and the subsequent development of Herceptin, the first targeted treatment for this type of breast cancer.View evidenceHide evidence
As statedfirst targeted treatment
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 8Not checkedHis team found that about 20% of breast cancers had multiple copies of HER2, and those tumors tended to be more aggressive with poorer outcomes.View evidenceHide evidence
As statedabout 20% of breast cancers
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 8Not checkedSlamon and collaborators showed that HER2 was actively driving tumor growth, making it a potential treatment target.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 8Not checkedEarly human trials of Herceptin showed that targeting HER2 with an antibody could have a positive clinical effect, and later randomized trials found that adding Herceptin to standard treatment significantly improved outcomes for patients with HER2-positive breast cancer.View evidenceHide evidence
As statedsignificantly improved outcomes
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 8Not checkedThe work led to FDA approval of Herceptin in 1998 and helped transform HER2-positive breast cancer into one of the breast cancers that can often be treated most successfully.View evidenceHide evidence
As stated1998
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 8Not checkedSlamon’s research also helped demonstrate the effectiveness of CDK4/6 inhibitors such as palbociclib and ribociclib in ER-positive breast cancer, which is now part of standard treatment.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Influencing Factors of Prognosis in Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer.
International Journal of Surgical Pathology · 2026 · PubMed, Europe PMC
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials
Cancer Treatment Reviews · 2017 · Crossref
Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.
The Lancet. Oncology · 2026 · PubMed
264 ORAL Concurrent trastuzumab and paclitaxel treatment improves disease-free survival in resected HER2-positive breast cancer: NCCTG N9831 interim analysis
European Journal of Cancer Supplements · 2005 · Crossref
Reassessing the Role of Anthracyclines in Early HER2-Positive Breast Cancer in the Era of HER2-Targeted Therapy and Treatment De-Escalation: A Systematic Review and Narrative Synthesis.
2026 · Europe PMC
And 10 more candidates considered.